Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
- Takeda Discontinues Development of Bipolar Disorder Treatment TAK-375SL
May 18, 2015
- Masanobu Kambara Becomes UCB Japan President
May 18, 2015
- Mochida Terminates License Deal with US Merck for Type 2 Diabetes Treatment
May 18, 2015
- MTPC Files Remicade for Kawasaki Disease
May 18, 2015
- Daiichi Sankyo Profit Quintuples on Gains from Ranbaxy-Sun Merger
May 15, 2015
- Eisai Earnings Pummeled by Generic Erosions in Japan, US
May 15, 2015
- Mitsubishi Chemical Group to Strengthen Presence in Field of Regenerative Medicine by Acquiring Clio Inc.
May 15, 2015
- Vital KSK Holdings Names Taisuke Murai as President
May 15, 2015
- Kyorin Holdings Names Minoru Hogawa as Next President
May 15, 2015
- Wider Indications Will Give Edge to Plavix AGs: Nichi-Iko Pres.
May 14, 2015
- Takeda Halts PIII Study of Aurora A Kinase Inhibitor for Peripheral T-cell Lymphoma
May 14, 2015
- Blopress AG Gives Lift to ASKA Sales and Profits
May 13, 2015
- Ono’s Operating Profit Declines 40%; NHI Price Reductions, Generics Had Major Negative Impact
May 13, 2015
- Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
- Denka Seiken to Start Development of Mass Production Technology for Therapeutic Oncolytic Virus for Cancer Therapy
May 13, 2015
- Ethical Drug Sales Down 5.2% in March: Crecon Report
May 13, 2015
- Shionogi Logs Record Ordinary Profit on Weaker Yen, ViiV Dividends
May 12, 2015
- Sumitomo Dainippon’s Profits Slide as Japan Sales Flounder
May 12, 2015
- Astellas Withdraws NDA for Nateglinide in Combination with DPP-4 Inhibitors
May 12, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…